Datapoints Summit

After leading drug discovery programs and advancing AI applications as a pharma and biotech leader, Stacie has recently joined NVIDIA to further enable AI adoption across the Healthcare and Life Sciences sector. She also serves as the Vice Chair of the Alliance for Artificial Intelligence in Healthcare (AAIH). In her 13+ years at GSK, she led R&D initiatives and co-led the ATOM consortium. More recently, she held leadership roles at AI Drug Discovery startups Atomwise, where she was a VP of Partnerships, and BioSymetrics, where she was the Chief Strategy Officer. Stacie holds a B.S. in Chemistry from UC Berkeley and a Ph.D. in Organic Chemistry from UC Irvine.

More details coming soon.

Jeff Waring received his B.S. in Chemistry with a minor in Biology from Central Michigan University in 1988. He then went to the University of Iowa where he obtained his PhD in Genetics. Following his thesis work, he was awarded an Alexander von Humboldt Fellowship for postdoctoral research in Germany at the University of Wurzburg and at the Institute for Molecular Pharmacology in Berlin. Following his postdoctoral research, Jeff began working at Abbott/AbbVie. He has served as Group Leader in the Department of Cellular and Molecular Toxicology, Neuroscience Discovery, and in the Neuroscience Biomarker Group. He is currently the Interim Head of the Genomics Research Center at AbbVie, comprised of a team of scientists that leverage cutting-edge Omics platforms, CRISPR technologies, and advanced computational approaches to drive the discovery and validation of innovative drug targets to enable breakthrough therapies for patients. Jeff has been a recipient of several President's Awards, and was named a Senior Research Fellow in the AbbVie Community of Science. Jeff has published over 90 articles in peer-reviewed journals, and has presented at numerous international conferences and serves on the Editorial Board of several journals.

More details coming soon.

More details coming soon.

Josh Haimson is the CEO and founder of Inductive Bio. Inductive Bio has developed a collaborative AI platform that dramatically accelerates compound optimization, a critical and time-consuming step in developing new therapeutics. Inductive's platform allows scientists to optimize initial compounds into leads and development candidates faster and with a better balance of ADMET properties. He spent his career focused on the intersection of machine learning, product, and life sciences/healthcare. Prior to Inductive, Josh was the Director of Product for the ML and data curation organizations at Flatiron Health, where his teams worked to generate real-world evidence (RWE) at scale across Flatiron's network of over 2 million active cancer patients for use by researchers in pharma, academia, and government. Prior to Flatiron, Josh was at MIT studying computer science and working with researchers at Massachusetts General Hospital to use ML and NLP to predict patient response to cardiac resynchronization therapy.

Dr. Robin Röhm is the co-founder and CEO of Apheris, a company that builds federated data networks for the life sciences industry. By providing a secure federated computing platform, Apheris allows organizations to collaboratively train higher-quality AI models on sensitive, multi-party data—overcoming the critical challenges of data silos, IP, and privacy concerns. Before founding Apheris, Robin studied Medicine, Philosophy and Mathematics at the University of Würzburg and was trained in global banking at UBS.

Dr. Garegin (Garyk) Papoian is the Chief Scientific Officer of Deep Origin, with expertise spanning quantum chemistry, protein folding and dynamics, chromatin biophysics, cytoskeletal modeling, and whole-cell simulations. A former Monroe Martin Professor at the University of Maryland and Founder of Biosim (merged with Deep Origin), he earned his PhD at Cornell University under Nobel Laureate Dr. Roald Hoffmann. Dr. Papoian is widely recognized for his pioneering work in computational chemistry and biophysics, with more than one hundred publications in leading international journals and national honors including the Beckman Young Investigator Award, Camille Dreyfus Teacher-Scholar Award, and NSF CAREER Award.

More details coming soon.

More details coming soon.

More details coming soon.

Jonathan Gilbert leads the growth of the Lilly TuneLab Ecosystem on the east coast of US and Europe. Jonathan received his PhD from MIT in Chemical Engineering and has spent his last decade plus in biotech at multiple companies ranging from the Seed stage to early clinical public companies. Immediately prior to Lilly, Jonathan lead Corporate Development and Strategy at Entact Bio.

Jason Perera is a Senior Manager for AI/ML at Biohub, where he leads work on virtual cell models of immune biology, along with the large-scale assays and open-source datasets needed to train them. He earned his PhD in Immunology from the University of Chicago studying immune cell tolerance. As an early member of Tempus Labs' Computational Immunology group, he built clinical and research pipelines for cancer diagnostics before moving to Genentech to develop individualized immunotherapies.

Nicholas Larus-Stone is Head of the AI Agents team at Benchling, where he leads development of the company's scientific agents and other AI-driven products. He joined Benchling following its acquisition of Sphinx Bio, the startup he founded to apply AI to scientific data analysis and drug discovery. Earlier in his career, he was the first software engineer at Octant Bio and led the Machine Learning Infrastructure team at BenevolentAI. Nicholas is also the founder and President of Bits in Bio, a leading nonprofit uniting innovators in software and life sciences.

Dr. Anna Westerhaus is a Discovery Postdoctoral Fellow in the Neuroscience Targets & Technologies Unit at Novartis. She earned her PhD in Biochemistry, Cellular, and Molecular Biology from Johns Hopkins University in 2024, where her dissertation focused on uncovering proteins and pathways contributing to neurodegeneration in ALS. During her graduate research, Anna developed expertise in a broad range of molecular, biochemical, and imaging techniques across various tissue and cell types. At Novartis, Anna has applied her skill set to cutting-edge genomic and transcriptomic approaches, including genome-wide CRISPR screening, to unravel mechanisms underlying neurodegenerative diseases and advance drug discovery efforts.

Kevin K. Yang's research focuses on developing machine learning methods to design and understand biomolecules. Specifically, his work aims to engineer novel and complex functions by combining advances in deep learning and experimental methods. Kevin is a principal researcher in the BioML group at Microsoft Research.